Screener
Taysha Gene Therapies, Inc. TSHA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $276,576 | $319,767 |
| Restricted cash | 449 | 449 |
| Prepaid expenses and other current assets | 5,225 | 4,431 |
| Total current assets | 282,250 | 324,647 |
| Restricted cash | 2,315 | 2,315 |
| Property, plant and equipment, net | 6,450 | 6,736 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s cash & equivalents?
- Taysha Gene Therapies, Inc. (TSHA) reported cash & equivalents of $276.58M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s cash & equivalents changed year-over-year?
- Taysha Gene Therapies, Inc.'s cash & equivalents increased by 137.2% year-over-year, from $116.59M to $276.58M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s cash & equivalents has grown at a 4.9% compound annual growth rate (CAGR), from $251.25M to $319.77M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Taysha Gene Therapies, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude